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ong-Term Outcomes After Stenting
f Bifurcation Lesions With the “Crush” Technique
redictors of an Adverse Outcome
ngela Hoye, MB CHB, PHD,* Ioannis Iakovou, MD,† Lei Ge, MD,† Carlos A. G. van Mieghem, MD,*
ndrew T. L. Ong, MD,* John Cosgrave, MD,† Giuseppe M. Sangiorgi, MD,† Flavio Airoldi, MD,†
atteo Montorfano, MD,† Iassen Michev, MD,† Alaide Chieffo, MD,† Mauro Carlino, MD,†
icola Corvaja, MD,† Jiro Aoki, MD,* Gaston A. Rodriguez Granillo, MD,* Marco Valgimigli, MD,*
eorgios Sianos, MD, PHD,* Willem J. van der Giessen, MD, PHD,* Pim J. de Feyter, MD, PHD,*
on T. van Domburg, PHD,* Patrick W. Serruys, MD, PHD,* Antonio Colombo, MD†
otterdam, the Netherlands; and Milan, Italy
OBJECTIVES The purpose of this study was to evaluate predictors of an adverse outcome after “crush”
bifurcation stenting.
BACKGROUND The “crush” technique is a recently introduced strategy with limited data regarding long-term
outcomes.
METHODS We identified 231 consecutive patients treated with drug-eluting stent implantation with the
“crush” technique for 241 de novo bifurcation lesions. Clinical follow-up was obtained in
99.6%.
RESULTS The in-hospital major adverse cardiac event (MACE) rate was 5.2%. At 9 months, 10 (4.3%)
patients had an event consistent with possible post-procedural stent thrombosis. Survival free
of target lesion revascularization (TLR) was 90.3%; the only independent predictor of TLR
was left main stem (LMS) therapy (odds ratio [OR] 4.97; 95% confidence interval [CI] 2.00
to 12.37, p  0.001). Survival free of MACE was 83.5% and independent predictors of
MACE were LMS therapy (OR 3.79; 95% CI 1.76 to 8.14, p  0.001) and treatment of
patients with multivessel disease (OR 4.21; 95% CI 0.95 to 18.56, p  0.058). Angiographic
follow-up was obtained in 77% of lesions at 8.3 3.7months. The mean late loss of the main
vessel and side branch were 0.30  0.64 mm and 0.41  0.67 mm, respectively, with binary
restenosis rates of 9.1% and 25.3%. Kissing balloon post-dilation significantly reduced the
side branch late lumen loss (0.24  0.50 mm vs. 0.58  0.77 mm, p  0.001).
CONCLUSIONS The crush technique of bifurcation stenting with drug-eluting stents is associated with
favorable outcomes for most lesions; however, efficacy appears significantly reduced in LMS
bifurcations, and further research is needed before the technique can be routinely recom-
mended in this group. Furthermore, the incidence of possible stent thrombosis is of concern
and requires further investigation. Kissing balloon post-dilatation is mandatory to reduce side
branch restenosis. (J Am Coll Cardiol 2006;47:1949–58) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.083of Cardiology Foundation
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ahe outcome of percutaneous coronary intervention of
ifurcation lesions with bare-metal stents (BMS) is hin-
ered by increased rates of procedural complications and
ong-term major adverse cardiac events (MACE) compared
ith non-bifurcated lesions (1). Randomized studies have
emonstrated that drug-eluting stents (DES) reduce reste-
osis when used in relatively simple lesions (2–5); and
ecent data have demonstrated efficacy of the sirolimus-
luting stent (SES) (Cypher, Cordis/Johnson & Johnson,
arren, New Jersey) for bifurcation lesions compared with
istorical data of BMS (6–8). In one study of bifurcation
From the *Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands;
nd the †EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy.
his study was supported by institutional grants from the Cordis Corporation
Johnson & Johnson) and Boston Scientific.g
Manuscript received August 28, 2005; revised manuscript received November 23,
005, accepted November 28, 2005.esions (6), the overall restenosis rate was 23%, with the
ajority of side branch restenoses occurring at the ostium
fter use of a T-stenting technique. Indeed, side branch
estenosis occurred in 16.7% after T-stenting, compared
ith 7.1% after other stenting techniques. We hypothe-
ized that these restenoses might relate to incomplete
overage of the side branch ostium thereby reducing the
fficacy of the DES.
The “crush” technique of bifurcation stenting with DESs
as introduced by Colombo et al. (9) in 2002 as a relatively
imple technique that ensures complete coverage of the side
ranch ostium (Fig. 1) thereby facilitating drug delivery at
his site. Initial data of 20 patients treated with this
echnique with SES suggest that it is a safe method, with an
cceptable rate of procedural complications and no further
dverse events up to 30 days’ follow-up. Recently, angio-
raphic data have shown the importance of simultaneous
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The Crush Technique of Bifurcation Stenting May 16, 2006:1949–58issing balloon post-dilation in reducing restenosis and need
or target lesion revascularization (10). We evaluated the
linical and angiographic outcomes of patients treated with
ither SES or paclitaxel-eluting stent (PES) (Taxus, Boston
cientific, Natick, Massachusetts) implantation with this
trategy at our institutions and evaluated the predictors of an
dverse outcome.
ETHODS
tudy population. Demographic and procedural data re-
arding all patients undergoing angioplasty at EMO Centro
uore Columbus, San Raffaele Hospital (Italy), and Tho-
axcenter (the Netherlands) are prospectively entered into
edicated databases. We identified all consecutive patients
ho underwent bifurcation stenting with the crush tech-
ique with DESs. Initially, therapy was undertaken with the
ES beginning in April 2002, when the SES received
onformité Européenne (CE) mark approval. In the first
Abbreviations and Acronyms
AMI  acute myocardial infarction
BMS  bare-metal stent
CABG  coronary artery bypass graft
CI  confidence interval
DES  drug-eluting stent
LMS  left main stem
MACE  major adverse cardiac event
MLD  minimal lumen diameter
OR  odds ratio
PES  paclitaxel-eluting stent
SES  sirolimus-eluting stent
TLR  target lesion revascularization
TVR  target vessel revascularization
igure 1. The crush technique of bifurcation stenting. (A) Baseline ang
ifurcation. (B) Both vessels are wired, and both stents are positioned. A 2
ell within the main vessel; at the same time, a 3.0  24 mm Taxus stent is wit
ide branch stent. (C) The side branch stent is deployed, and the balloon is wiuarter of 2003, patients could also be treated with the PES.
atients with either stable or unstable angina were included
f they were treated for a de novo bifurcation lesion. Those
ith acute ST-segment elevation myocardial infarction were
xcluded. Sirolimus-eluting stents were available in diame-
ers from 2.25 mm to 3.00 mm and lengths from 8 mm to
3 mm; PESs were available in diameters from 2.25 mm to
.5 mm and lengths from 8 mm to 32 mm.
rocedures and intervention medications. The crush
echnique is depicted in Figure 1 and has been previously
escribed (9). In short, the procedure requires a guide catheter
f 7-F. Both the main vessel and side branch are wired and
repared for stent implantation with pre-dilatation as neces-
ary. The stents are both positioned such that the proximal part
f the side branch lies well within the main vessel but is
ompletely covered by the stent within the main vessel (Fig.
B). The side branch stent is deployed and the balloon
arefully removed ensuring that the stent in the main vessel
emains fixed. The wire within the side branch is commonly
lso removed, although providing that the wire is not hydro-
hilic, it might be kept in position. The stent in the main vessel
s deployed, thereby crushing the proximal part of the side
ranch stent (and trapping the side branch wire if still in situ).
f present, the wire in the side branch can then be withdrawn,
nd post-dilation of the main vessel stent with high-pressure
alloon inflation facilitates use of a wire to re-cross into the side
ranch to allow kissing balloon post-dilation. Kissing balloon
ost-dilation was undertaken at the operator’s discretion. The
rotocol was approved by the institutional ethics committees
nd is in accordance with the principles of Good Clinical
ractice for Trials of Medicinal Products in the European
ommunity and the Declaration of Helsinki. All patients
igned a written informed consent.
with significant stenosis of the left anterior descending/first diagonal
12 mm Taxus stent is positioned in the side branch with its proximal partiogram
.5 hin the main vessel, ensuring it completely covers the proximal part of the
thdrawn. (D) The stent in the main vessel is deployed. (E) Final result.
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May 16, 2006:1949–58 The Crush Technique of Bifurcation StentingDuring the procedure, intravenous heparin was given to
aintain an activated clotting time 250 s. Patients were
reloaded with 300 mg clopidogrel and received life-long
spirin together with 75 mg clopidogrel/day for at least 6
onths. The use of glycoprotein IIb/IIIa inhibitors was at
he operator’s discretion.
linical definitions and follow-up. Clinical follow-up
as obtained with either telephone calls or office visit and
valuated the rate of MACE, pre-defined as death, acute
yocardial infarction (AMI), or target vessel revasculariza-
ion (TVR). The diagnosis of AMI both peri-procedural
nd at follow-up required an elevation of creatine kinase
evels to twice the upper limit of normal, together with a rise
n creatine kinase-MB fraction. When in addition to en-
yme elevation there were new pathological Q waves on the
lectrocardiogram, the event was defined as Q-wave myo-
ardial infarction. Target lesion revascularization (TLR)
as defined as either surgical or percutaneous reintervention
riven by significant (50%) luminal diameter narrowing
Table 1. Baseline Patient Demographics
n
Mean age (yrs) 62.8
Male (%) 193
Current smoker (%) 44
Diabetes mellitus (%) 46
Hypertension (%) 125
Hypercholesterolemia (%) 162
Family history (%) 103
Previous myocardial infarction (%) 95
Previous CABG (%) 33
Multivessel disease (%) 174
Clinical presentation
Stable angina (%) 172
Unstable angina (%) 59
Glycoprotein IIb/IIIa inhibitor usage (%) 73
p value for the sirolimus-eluting stent (SES) group versus p
CABG  coronary artery bypass graft surgery.
Table 2. Baseline Procedural Characteristics
n
Target vessel
LAD/diagonal (%) 13
LCX/obtuse marginal (%) 5
RCA bifurcation (%) 1
LMS (%) 4
Mean number of stents in the main vessel 1.2
Mean nominal diameter of stent in the
main vessel (mm)
3.01
Mean total length of stents in the
main vessel (mm)
29.3
Mean number of stents in the side branch 1.1
Mean nominal diameter of stent in the
side branch (mm)
2.62
Mean total length of stents in the
side branch (mm)
21.3
Post-dilation with kissing balloons (%) 12p value for the sirolimus-eluting stent (SES) group versus paclitax
LAD  left anterior descending artery; LCX  circumflex arteither within the stent or the 5 mm borders proximal and
istal to the stent and was undertaken in the presence of
ither anginal symptoms or objective evidence of ischemia.
arget vessel revascularization was defined as revasculariza-
ion within the target vessel including encompassing the
arget lesion.
Stent thrombosis was defined as an acute coronary syn-
rome with angiographic documentation of either vessel
cclusion or thrombus within or adjacent to a previously
uccessfully stented vessel or, in the absence of angiographic
onfirmation, either acute AMI in the distribution of the
reated vessel or death not clearly attributable to other
auses (11,12). Stent thrombosis was categorized according
o the timing of the event into: intra-procedural (angio-
raphic, confirmed intra-luminal filling defect within the
tent that occurred during the index procedure) (13), acute
occurred within the first 24 h after the procedure), subacute
from 24 h to 30 days), and late (30 days after the index
rocedure).
1
SES
n  130
PES
n  101 p Value
.2 62.9  11.2 62.6  11.1 0.76
) 113 (86.9) 80 (79.2) 0.15
) 24 (18.5) 20 (19.8) 0.87
) 25 (19.2) 21 (20.8) 0.74
) 76 (58.5) 49 (48.5) 0.14
) 91 (70.0) 71 (70.3) 1.0
) 53 (40.8) 50 (49.5) 0.23
) 48 (36.9) 47 (46.5) 0.22
) 18 (13.8) 15 (14.9) 0.85
) 98 (75.4) 76 (75.2) 1.0
1.0
) 96 (73.8) 76 (75.2)
) 34 (26.2) 25 (24.8)
) 53 (40.8) 20 (19.8) 0.001
el-eluting stent (PES) group.
1
SES
n  137
PES
n  104 p Value
0.15
9) 82 (59.9) 48 (46.2)
6) 28 (20.4) 24 (23.1)
) 6 (4.4) 6 (5.8)
5) 21 (15.3) 26 (25.0)
.5 1.24  0.51 1.22  0.50 0.82
.32 2.95  0.29 3.09  0.34 0.001
1.3 30.31  10.96 28.05  11.58 0.12
.3 1.08  0.32 1.03  0.26 0.18
.32 2.58  0.30 2.68  0.34 0.02
.3 21.45  10.11 21.01  8.28 0.72
6) 58 (42.3) 64 (61.5) 0.004All
 23
 11
(83.5
(19.0
(19.9
(54.1
(70.1
(44.6
(41.1
(14.3
(75.3
(74.5
(25.5
(31.6All
 24
0 (53.
2 (21.
2 (5.0
7 (19.
 0
 0
 1
 0
 0
 9
2 (50.el-eluting stent (PES) group.
ry; LMS  left main stem; RCA  right coronary artery.
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The Crush Technique of Bifurcation Stenting May 16, 2006:1949–58ngiographic evaluation. Procedural angiographic success
as defined as a post-procedural final residual stenosis
50% with Thrombolysis In Myocardial Infarction flow
rade 3 in both the main vessel and side branch. Between 6
nd 12 months after the index procedure, all living patients
ere invited back for angiographic follow-up. Coronary
ngiograms were obtained in multiple views after intracoro-
ary injection of nitrates. Quantitative coronary angiographic
QCA) analysis was performed with one of two validated edge
etection systems (CMS, version 5.2, MEDIS, Leiden, the
etherlands; and the Cardiovascular Angiography Analysis
ystem II [CAAS II], Pie Medical, Maastricht, the Nether-
ands). The reference vessel diameter, minimal lumen diameter
MLD), and percent diameter stenosis were measured at
re-procedure, post-procedure, and follow-up. Reference
essel diameter for the side branch was taken as the
iameter of the normal vessel distal to the bifurcation. The
ate lumen loss was calculated as the difference between the
ost-procedure and follow-up MLD (14). Binary restenosis
as defined as the presence of 50% diameter stenosis
ithin the target lesion.
tatistical analysis. Discrete variables are presented as
ercentages and compared with Fisher exact test. Continu-
us variables are expressed as mean  standard deviation
nd compared with Student t test. Cumulative survival free
f adverse events was calculated according to the Kaplan-
eier method. Logistic regression models were established
o investigate independent predictors of TLR and MACE.
he following clinical variables were entered into the
nalysis model: age, gender, diabetes, stent type, unstable
ngina, premature antiplatelet therapy discontinuation, left
ain stem (LMS) bifurcation, glycoprotein IIb/IIIa inhib-
tor use, kissing balloon post-dilation, nominal stent diam-
Table 3. Clinical Outcomes
Al
n 
In-hospital MACE, n (%) 11 (4
Cardiac death, n (%) 0
Acute myocardial infarction, n (%) 11 (4
Q-wave myocardial infarction 1 (0
Non–Q-wave myocardial infarction 10 (4
Target lesion revascularization, n (%) 1 (0
Target vessel revascularization, n (%) 1 (0
p value for the sirolimus-eluting stent (SES) group versus p
MACE  major adverse cardiac events.
Table 4. Cumulative Survival Free of MACE
Survival (%)
Survival free of Q-wave AMI (%)
Survival free of AMI (Q-wave or non–Q-wave) (%)
Survival free of target lesion revascularization (%)
Survival free of target vessel revascularization (%)
Survival free of MACE (%)p value for the sirolimus-eluting stent (SES) group versus paclitax
AMI  acute myocardial infarction; MACE  major adverseter, and stent length. Odds ratios (ORs) with correspond-
ng 95% confidence intervals (CIs) are reported. All tests
ere two-tailed, and a p value of 0.05 was considered
ignificant.
ESULTS
he crush technique was used in 231 patients (241 lesions),
ith SES in 137 (56.8%), and PES in 104 (43.2%). The
aseline patient and procedural characteristics are presented
n Tables 1 and 2. The use of glycoprotein IIb/IIIa inhibitor
herapy was significantly higher in the SES group than in
he PES group (40.8% vs. 19.8%, p  0.001). Attempted
issing balloon post-dilatation was undertaken in 128 le-
ions and was successful in 122 (95%) cases; it was carried
ut more frequently in the PES group (61.5% vs. 42.3% in
ES, p  0.004).
linical outcomes. The rate of in-hospital adverse events
s shown in Table 3. There were three (1.3%) intra-
rocedural stent thromboses (two in the SES group, one in
he PES group); two of these developed non–Q-wave AMI.
he mean total stent length of these three cases was 69 mm,
nd no glycoprotein IIb/IIIa inhibitor had been given
lectively. After thrombolytic therapy and further balloon
nflation, thrombosis resolved. One additional patient in the
ES group developed a Q-wave myocardial infarction in
ospital due to occlusion of septal branches during the index
rocedure. By logistic regression analysis, the only predictor
or in-hospital MACE was the use of a glycoprotein
Ib/IIIa inhibitor in patients (OR 3.25; 95% CI 0.99 to
0.60, p  0.051).
Clinical follow-up data at nine months was available in
9.6% of patients. The cumulative rates of survival free of
SES
n  130
PES
n  101 p Value
5 (3.8) 6 (5.9) 0.5
0 0 1.0
5 (3.8) 6 (5.9) 0.5
1 (0.8) 0 0.4
4 (3.1) 6 (5.9) 0.3
1 (0.8) 0 0.4
1 (0.8) 0 0.4
el-eluting stent (PES) group.
ne Months
All
n  241
SES
n  137
PES
n  104 p Value
98.7 99.2 98.0 0.42
96.5 96.9 96.0 0.72
90.8 93.1 88.0 0.20
90.3 93.8 85.5 0.046
89.0 93.0 83.6 0.028
83.5 87.7 78.0 0.053l
231
.8)
.8)
.4)
.3)
.4)
.4)at Niel-eluting stent (PES) group.
cardiac event.
Table 5. Patients With a Definite or Probable Post-Procedural Stent Thrombosis
Patient
No.
Age/
Gender
Stent
Type DM
Multivessel
Disease
Previous
CABG
Target
Vessel
Index
Presentation
Index Use of
GP IIb/IIIa
Inhibitor
Kissing Balloon
Post-Dilation
Time to Definite
or Probable
Thrombosis, days
Dual Antiplatelet
Therapy at the Time
of the Event
Presentation and
Therapy of
Thrombosis
1 74 yrs/
F
SES N Y N LAD SA N Y 1 Y AMI: underwent
TLR with
PCI, alive
2 66 yrs/
F
PES N Y N LCx UA N N 7 Y AMI: underwent
TLR with
PCI, alive
3 67 yrs/
M
PES N Y Y LMS SA N Y 145 Y AMI: managed
medically, alive
4 73 yrs/
M
PES Y Y Y LMS SA N N 204 N Sudden death
Stopped clopidogrel
at 6 months
5 41 yrs/
M
PES N Y N LAD UA N N 211 N AMI: managed
medically, aliveStopped clopidogrel
at 6 months
6 82 yrs/
M
SES Y Y N LMS UA Y Y 55 N Death
Stopped clopidogrel
because of
pancreatitis
7 61 yrs/
M
PES N Y Y LMS SA Y Y 63 Y AMI and death
8 71 yrs/
M
PES N Y N LMS SA N Y 117 Y AMI: managed
medically, alive
9 65 yrs/
F
PES Y N N LAD SA Y N 166 Y AMI: managed
medically, alive
10 80 yrs/
M
SES Y Y N LAD SA Y N 28 N AMI: managed
medically, aliveStopped clopidogrel
because of
abdominal surgery
AMI  acute myocardial infarction; CABG  coronary artery bypass graft surgery; DM  diabetes mellitus; LAD  left anterior descending artery; LCx  left circumflex artery; LMS  left main stem; N  no; PCI  percutaneous
coronary intervention; PES  paclitaxel-eluting stent; SA  stable angina; SES  sirolimus-eluting stent; TLR  target lesion revascularisation; UA  unstable angina; Y  yes.
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The Crush Technique of Bifurcation Stenting May 16, 2006:1949–58ACE are shown in Table 4. Post-procedural, angio-
raphically confirmed stent thrombosis occurred in two
0.9%) patients (one acute, one subacute) who were both
ubsequently treated with glycoprotein IIb/IIIa inhibitor
herapy and percutaneous TLR. In addition, three patients
ied, and five patients had an AMI within the territory of the
reated vessel, giving a total rate of possible post-procedural
tent thrombosis of 4.3%. The demographics of these 10
atients are presented in Table 5. The incidence of post-
rocedural stent thrombosis was higher for the PES group
han the SES group (6.9% vs. 2.2%, p  0.08).
The overall rates of survival free of MACE and TLR
ere 83.5% and 90.3%, respectively (Fig. 2). Independent
redictors for MACE were therapy of the LMS (OR 3.79;
5% CI 1.76 to 8.14, p  0.001) and therapy of patients
ith multivessel disease (OR 4.21; 95% CI 0.95 to 18.56,
 0.058). Significantly fewer of the SES treated patients
equired TLR compared with those treated with PES;
owever, logistic regression demonstrated that the only
ndependent factor for TLR was therapy of the LMS (OR
.97; 95% CI 2.00 to 12.37, p 0.001). The rate of survival
ree of TLR was 77.8% in those who underwent LMS
tenting compared with 94.2% in the remainder (Fig. 3).
uantitative angiographic analysis. Procedural angio-
raphic success was achieved in 99.6% of lesions. Follow-up
oronary angiography was undertaken in 186 (77.2%) le-
ions, at a mean period of 8.3  3.7 months. Angiographic
ata with respect to the stent type and the use of kissing
alloon post-dilation are presented in Tables 6 and 7. There
as no significant difference in angiographic results with
espect to the type of stent used; however, kissing balloon
ost-dilation significantly reduced the side branch late
umen loss and binary restenosis. Among the 47 restenotic
esions at the side branch, 34 (72.3%) were focal (10 mm)
igure 2. Cumulative survival free of target lesion revascularization (TLR)
nd major adverse cardiac events (MACE) after bifurcation stenting with
he crush technique.nd located at the ostium.
l
oISCUSSION
he main findings of this report are: 1) treatment of most
ifurcation lesions with DES by the “crush” technique is
ssociated with low rates of TLR and MACE at nine
onths, however, therapy of the LMS was an independent
redictor of both TLR and MACE; 2) at nine months, the
ncidence of possible post-procedural stent thrombosis was
.3%; and 3) the rate of side branch restenosis was signifi-
antly lower in lesions treated with kissing balloon post-
ilation compared with those without.
tent coverage of the ostium of the side branch and
linical outcomes. Bifurcation lesions are subject to in-
reased rates of restenosis and need for TLR compared with
on-bifurcated lesions. Historical data of BMSs suggest a
LR rate of 16% to 38%, with a tendency toward increased
estenosis after stenting of both the main vessel and side
ranch compared with single vessel stenting (15–19). In the
ame studies, the rate of MACE at six months ranged
etween 17% and 51%. In randomized studies of relatively
imple lesions, DESs reduce restenosis compared with
MSs, although bifurcation lesions were excluded (2–5).
reliminary data for the SES has recently suggested efficacy
n bifurcation lesions (6–8); however, the most effective
tenting strategy is currently unknown. Previous data of the
ES suggested a higher restenosis rate after T-stenting,
ith the hypothesis that this might relate to incomplete
overage of the side branch ostium (6,7). In most bifurca-
ions, the angle at the carina is significantly smaller than 90°,
eaning that even with precise positioning, the stents are
nable to make a “T” and completely cover the bifurcation
18). The crush technique is a relatively simple strategy that
nsures complete lesion coverage, even for bifurcation le-
ions that have extensive disease within the side branch.
reliminary data have pointed to acceptable short-term
esults suggesting that it might therefore be an effective
trategy for bifurcation lesions (9).
igure 3. Cumulative survival free of target lesion revascularization (TLR)
or patients treated with the crush technique of bifurcation stenting for a
eft main stem (LMS) lesion compared with those treated for lesions
utside the left main stem (non-LMS).
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May 16, 2006:1949–58 The Crush Technique of Bifurcation StentingIn the present study, we have demonstrated encouraging
ong-term results, with a high rate of survival free of TLR of
0.3%. Although TLR rates were higher in those treated
ith PES compared with SES, there were more patients in
his group treated for LMS bifurcation (25.0% vs. 15.3%).
y logistic regression analysis, therapy of the LMS was the
nly independent predictor of TLR. Indeed, at nine
onths, the rate of survival free of TLR was 77.8% in those
ho underwent LMS stenting, compared with 94.2% in the
emainder. The rate of in-hospital MACE was 4.8%, the
ajority comprising non–Q-wave AMI. The MACE rate
as higher in those who received a glycoprotein IIb/IIIa
nhibitor; however, this is likely to reflect the operators’
ecision to use such an agent only in the situation of a
ifficult or complicated procedure. There is evidence to
uggest improved efficacy of glycoprotein IIb/IIIa inhibitors
ith early administration. Further work is needed to eval-
ate whether routine pre-procedural administration of such
gents to all patients undergoing crush stenting might
educe the occurrence of in-hospital events.
At nine months, the overall rate of survival free of
ACE was 83.5%. Independent predictors were the treat-
ent of multivessel disease and treatment of the LMS.
ecent data have been published specifically evaluating the
esults of LMS stenting with DES implantation (20–23).
n all these studies, results suggested lower rates of reste-
osis compared with historical data of BMS. The incidence
f TLR ranged from 2.0% to 14.1%. This appears to be
Table 6. Quantitative Coronary Angiography
All
Follow-up angiography, n (%) 186 (77
Main branch
Reference diameter (mm) 2.71  0
Length of lesion (mm) 15.38  1
Minimal lumen diameter (mm)
Pre-procedure 0.93  0
Post-procedure 2.73  0
6-month follow-up 2.43  0
Diameter stenosis (%)
Pre-procedure 65.9  1
Post-procedure 13.0  8
6-month follow-up 22.9  1
Late lumen loss (mm) 0.30  0
Binary restenosis rate (%) 17 (9.
Side branch
Reference diameter (mm) 2.39  0
Length of lesion (mm) 8.99  6
Minimal lumen diameter (mm)
Pre-procedure 0.89  0
Post-procedure 2.26  0
6-month follow-up 1.85  0
Diameter stenosis at 6 months (%)
Pre-procedure 62.3  2
Post-procedure 15.5  9
6-month follow-up 30.7  0
Late lumen loss (mm) 0.41  0
Restenosis rate (%) 47 (25
p value for the sirolimus-eluting stent (SES) group versus puch lower than the LMS cohort in our study where the tate of survival free of TLR was just 77.8% (compared with
4.2% for non-LMS lesions); however, in the aforemen-
ioned studies, restenosis after LMS bifurcation stenting
as higher compared with lesions localized to the ostium or
ody of the LMS. Chieffo et al. (22) evaluated 85 patients,
ncluding 69 (81.2%) with disease of the distal LMS. The
ajority of these patients were treated with stent implan-
ation to both branches, most (59%) with crush stenting. All
2 patients who required TLR were initially treated with a
wo-stent strategy. Park et al. (21) demonstrated excellent
esults after LMS angioplasty, with a binary restenosis rate
f 7.0%. In this study, 70.6% patients were treated for the
MS bifurcation, and all restenoses occurred in these patients.
issing balloon post-dilation. Although the overall rate
f TLR in the present study was relatively low, kissing
alloon post-dilation had a significant impact on the angio-
raphic results, leading to a significantly larger post-
rocedural MLD within both the main vessel and side
ranch. This larger MLD was maintained in both vessels at
ollow-up but was particularly evident within the side
ranch. As previously demonstrated by Ge et al. (10),
issing balloon post-dilation in the present study signifi-
antly reduced both the side branch late lumen loss (0.24 
.50 mm vs. 0.58  0.77 mm, p  0.001) and binary
estenosis rate (9.6% vs. 41.3%, p  0.000001).
The majority (72.3%) of these side branch restenoses
ere focal and occurred at the ostium. Bench study results
ave demonstrated the crush technique to effectively cover
SES PES p Value
107 (78.1) 79 (76.0) 0.8
2.71  0.58 2.71  0.61 1.0
15.99  9.09 14.57  12.06 0.4
0.90  0.53 0.98  0.52 0.3
2.70  0.51 2.77  0.62 0.4
2.40  0.76 2.47  0.89 0.6
67.3  17.1 63.9  18.0 0.2
13.6  8.3 12.1  9.0 0.3
24.1  19.1 21.3  21.1 0.3
0.30  0.60 0.30  0.70 1.0
10 (9.3) 7 (8.9) 1.0
2.36  0.45 2.41  0.60 0.6
9.64  6.12 8.04  5.80 0.09
0.92  0.51 0.86  0.53 0.5
2.26  0.49 2.26  0.55 1.0
1.89  0.85 1.81  0.87 0.5
60.9  20.6 64.3  20.3 0.3
15.0  9.7 16.2  9.3 0.4
29.4  27.7 32.5  27.3 0.5
0.37  0.71 0.46  0.60 0.4
29 (27.1) 18 (22.8) 0.6
el-eluting stent (PES) group..2)
.59
0.46
.52
.56
.81
7.5
.6
9.9
.64
1)
.51
.03
.52
.51
.86
0.5
.5
.67
.67
.3)he bifurcation lesion; however, the absence of kissing
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pposition of the side branch stent struts (24). Kissing
alloon post-dilation opens the struts, thereby facilitating
ccess to the side branch, and corrects stent deformation to
rovide optimal scaffolding and delivery of drug. The crush
echnique is technically relatively quick and simple; kissing
alloon post-dilation increases the procedural time and cost,
lthough our results suggest that it is a necessity.
After stent implantation, it can be difficult and time-
onsuming to re-cross the side branch with a wire and/or
alloon. We recommend routine post-dilation of the main
essel stent with a balloon (nominal stent diameter) taken
o high pressure. After this, successful access of the side
ranch and subsequent post-dilation can be achieved in
95% of procedures. Stent under-expansion remains one of
he major reasons for restenosis (25), even in the DES era
26–28). To enable full stent strut expansion at the side
ranch ostium, we initially perform high-pressure (12
tm) balloon inflation in the side branch with a balloon
nominal stent diameter (29). Once both the main vessel
nd side branch stents have been individually post-dilated at
igh pressure, kissing balloon post-dilation is then under-
aken. Notably, the aforementioned bench study (24) em-
hasized that optimal kissing dilation requires the size of
he balloon in the main vessel greater than or equal to the
ominal stent diameter.
Bifurcation stenting is known to increase the risk of
Table 7. Quantitative Coronary Angiography W
Post-Dilation
Kissing
Post-D
Follow-up angiography, n (%) 94 (
Main branch
Reference diameter (mm) 2.78 
Length of lesion (mm) 14.84 
Minimal lumen diameter (mm)
Pre-procedure 0.97 
Post-procedure 2.89 
6-month follow-up 2.64 
Diameter stenosis (%)
Pre-procedure 65.5 
Post-procedure 12.2 
6-month follow-up 19.9 
Late lumen loss (mm) 0.26 
Binary restenosis rate (%) 6 (
Side branch
Reference diameter (mm) 2.45 
Length of lesion (mm) 9.01 
Minimal lumen diameter (mm)
Pre-procedure 0.90 
Post-procedure 2.43 
6-month follow-up 2.18 
Diameter stenosis at 6 months (%)
Pre-procedure 62.7 
Post-procedure 12.8 
6-month follow-up 20.5 
Late lumen loss (mm) 0.24 
Restenosis rate (%) 9 (estenosis with BMS. Accordingly, compared with the tesults of randomized studies of non-bifurcation lesions, our
esults suggest that this also applies to DESs. Compared
ith the Sirolimus-Eluting Stent in De Novo Native
oronary Lesions (SIRIUS) study (4), the SES patients in
ur study demonstrated a higher rate of TLR (5.4% vs.
.1%). Similarly, compared with the results of Paclitaxel-
luting Coronary Stent System (TAXUS)-IV (5), the PES
atients in our study demonstrated a higher rate of TLR
11.9% vs. 3.0%). In addition, compared with these pub-
ished studies, both groups of patients in our study had a
igher main vessel late lumen loss (0.30 0.60 mm vs. 0.24
.47 mm for the SES, and 0.30  0.70 mm vs. 0.23  0.44
m for the PES).
tent thrombosis. The 1.3% incidence of intra-procedural
tent thrombosis in the present report is slightly higher than
he incidence previously reported in a large series of patients
reated with SES (0.7%) (12). The 4.3% incidence of
ost-procedural stent thrombosis is of concern and is higher
han the findings of the trials that evaluated DES implan-
ation in relatively simple lesions (0.4% for SES and 0.6%
or PES) (4,5). This might reflect the complexity of the
echnique with an increased risk of thrombosis perhaps
eflecting the triple layer of stent struts, polymer, and drug
t the site of the carina. Notably, in the present study,
issing balloon post-dilation did not appear to reduce the
isk of stent thrombosis.
The incidence of post-procedural stent thrombosis
Respect to the Use of Kissing Balloon
on
on
No Kissing Balloon
Post-Dilation p Value
92 (77.3) 1.0
1 2.64  0.57 0.1
40 15.97  10.55 0.5
3 0.89  0.52 0.3
4 2.55  0.53 0.0001
1 2.21  0.75 0.001
1 66.4  18.0 0.7
13.8  8.5 0.2
2 26.1  19.3 0.04
5 0.35  0.64 0.3
11 (12.0) 0.2
3 2.32  0.49 0.1
6 8.97  6.03 1.0
3 0.88  0.52 0.8
3 2.10  0.44 0.00001
1 1.52  0.86 0.0000001
7 61.9  20.3 0.8
18.3  9.5 0.0001
9 41.0  31.5 0.000001
0 0.58  0.77 0.001
38 (41.3) 0.000001ith
Ballo
ilati
77.0)
0.6
10.
0.5
0.5
0.8
17.
8.7
20.
0.6
6.4)
0.5
6.0
0.5
0.5
0.7
20.
8.7
17.
0.5ended to be higher in the cohort treated with the PES
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May 16, 2006:1949–58 The Crush Technique of Bifurcation Stentingompared with the SES (6.9% vs. 2.2%). This is in
ccordance with the recently presented results of the Pro-
pective Randomized Multi-center Head-to-Head Com-
arison of the Sirolimus-Eluting Stent (REALITY) study
30). This multicenter study randomized 1,353 patients
1,911 lesions) to therapy with either SES or PES. There
as a higher rate of stent thrombosis in the PES-treated
roup (1.8% vs. 0.4%, p  0.02). In the present study, such
high incidence of thrombosis emphasizes the importance
f an aggressive strategy of antiplatelet therapy, with ad-
inistration of dual antiplatelet therapy for a prolonged
though as yet undefined) period of time. Indeed, 4 of the
0 patients had stopped clopidogrel before the presumed
hrombotic event. A recent study has shown that premature
iscontinuation of dual antiplatelet therapy is associated
ith an approximately 30-fold greater risk of stent throm-
osis after SES implantation (11). For patients treated with
he crush technique, premature discontinuation of antiplate-
et therapy has been shown to be a predictor of stent
hrombosis (10) and, in conjunction with our results,
uggests that the technique should not be recommended in
atients who cannot receive or tolerate dual antiplatelet
herapy. Further work is needed to evaluate the potential
enefit of routine pre-procedural administration of glyco-
rotein IIb/IIIa inhibitor therapy to all patients treated with
his technique.
tudy limitations. The main limitation of the present
eport is its non-randomized design; therefore, caution must
e taken in evaluating any differences between the stent
ypes. Furthermore, the study does not make comparison
ith alternative stenting strategies. The decision to use both
lycoprotein IIb/IIIa inhibitor therapy and the use of
issing balloon post-dilation was at the operators’ discretion
nd was therefore also not randomized.
onclusions. The crush technique of bifurcation stenting
ith DESs is associated with favorable clinical outcomes
hen compared with historical data of BMS; however, the
ncidence of possible post-procedural stent thrombosis is of
oncern and is higher than that after therapy of more simple
esions, suggesting that an aggressive strategy of anti-
latelet therapy might be of importance. Notably, the
fficacy of the technique appears to be reduced in LMS
ifurcation lesions, and further research is needed before the
echnique can be routinely recommended in this group of
atients. When using this technique, kissing balloon post-
ilatation is mandatory to reduce the rate of restenosis of the
ide branch. Randomized studies are warranted to directly
ompare the technique with other bifurcation stenting
trategies.
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